According to a new report published by Introspective Market Research, titled, “Antiviral Drugs Market by Type (Branded, Generics), Application (Influenza, HIV, Hepatitis, Coronavirus Infection, Others), Age Group (Adult, Pediatric), Mechanism of Action (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), And Region Global Market Analysis and Forecast, 2023-2030,” the global Antiviral Drugs market size was valued at $ 61.42 billion in 2020, and is projected to reach $80.28 billion by 2030, registering a CAGR of 3.9% from 2023 to 2030. Antiviral medications are a kind of medication used to either destroy or suppress a virus's ability to replicate, preventing the virus from having the ability to spread and multiply. The genetic material that makes up viruses, such as DNA or RNA, is alive when it is outside in the environment but becomes capable of reproducing and spreading when it enters a host that is vulnerable to it. Antiviral medications can also shield patients from contracting viral illnesses and preventing the virus from infecting new people. The development of antivirals is the result of recent advancements in drug discovery techniques, a focus on treating the human immunodeficiency virus (HIV), which is the cause of acquired immunodeficiency syndrome, and newly gained knowledge of the molecular and genetic activity of organisms, which allows us to better understand the structure and function of viruses. These factors are expected to drive market growth during the forecast period.
Antiviral medications have the benefit of being able to treat certain viral diseases, such as hepatitis C, or shorten the duration of other viral diseases, such as influenza. Antiviral medications can be used to stop the spread of some viral diseases, such as herpes. Anti-viral drug properties also include the ability to penetrate virus-infected cells and disrupt the synthesis of viral nucleic acids, which limits the virus's capacity to multiply and spread, supporting the market's growth during the forecast period. The number of viral disease outbreaks has significantly increased recently; therefore, antiviral medications are needed to prevent such outbreaks, which will support the market's growth during the projection.
The main opportunity for market players is the rising number of viral illnesses and the rising demand for antiviral medications. Additionally, a number of governments are spending enormous sums of money on R&D in order to supply their citizens with antiviral medications, which presents a wealth of opportunity for market participants. For market participants, developing broad-spectrum antiviral medications with encouraging outcomes is a crucial opportunity.
Global Antiviral Drugs Market, Segmentation
The Antiviral Drugs market is segmented based on type, application, Age Group, Mechanism of Action and region.
Drug Action Mechanisms:
Reverse transcriptase inhibitors are predicted to hold the largest proportion. The main factors encouraging the use of reverse transcriptase inhibitors are the rising number of HIV patients worldwide and the effectiveness of these medications to treat HIV infection. Because protease inhibitors can stop HIV from spreading to healthy cells, they are predicted to hold the second-highest market share among antiviral drugs.
Application:
The number of people living with HIV is rising, the HIV market is predicted to dominate the antiviral medicine industry. Because of immunization against hepatitis A and hepatitis B, HIV is thought to hold the second-largest share of the antiviral medicine market, behind hepatitis.
Region:
North America is expected to lead the antiviral medicine market over the forecast period. The United States government is taking a number of actions, such as funding programs for infectious diseases and promoting research and development of novel treatments to treat viral infections.
Some of The Leading/Active Market Players Are-
- Gilead Sciences Inc (US)
- AbbVie Inc (US)
- Merck & Co Inc (US)
- Johnson & Johnson Services Inc (US)
- Teva Pharmaceutical Industries Ltd (Israel) Regeneron Pharmaceuticals Inc (US)
- Bristol-Myers Squibb Company (US)
- GlaxoSmithKline plc (UK)
- AstraZeneca (UK)
- Zydus Cadila (India)
- Cipla Inc (India) and Other Active Players
Key Industry Developments
In April 2022, European Medicines Agency, the European Union's drug regulator, signed off on emergency usage of Merck's Covid antiviral pill for adults who get tested positive as it prepares to decide on full approval by the year's end.
In September 2021, Gilead Sciences Inc declared the results of their phase 3 trial to evaluate the efficiency and safety of a three-day course of Veklury (Remdesivir). The results are remarkable as they showed positive effects for the treatment of COVID-19 in non-hospitalized patients who were at high risk for disease progression. The study involved 562 participants. These fresh data emphasize remdesivir's capability to aid the high-risk patient to recover before the advancement of the disease and stay out of the hospital.
Key Findings of the Study
- Reverse transcriptase inhibitors are anticipated to hold the largest market share due to their efficacy in treating HIV infections, followed by protease inhibitors, highlighting the significance of HIV treatment in the market.
- The HIV segment is expected to dominate the application segment, driven by the increasing number of people living with HIV globally, while North America leads in market share due to significant government investments in infectious disease research and development initiatives.
- Opportunities lie in developing broad-spectrum antiviral drugs and meeting the rising demand for antiviral medications amid a surge in viral disease outbreaks, with governments investing heavily in R&D to address these needs.
